vesicle transport through interaction with t-SNAREs 1B pseudogene 4Genealiases: []
Q-omics provides the consensus-scored VTI1BP4 profile across patient tissues and cancer cell-line models. VTI1BP4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, VTI1BP4 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, VTI1BP4 RNA expression shows 6,546 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, COAD, and STAD as cancer lineages where VTI1BP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VTI1BP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VTI1BP4 survival associations across molecular data types. VTI1BP4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VTI1BP4 RNA expression–survival associations across cancer types. High VTI1BP4 expression shows unfavorable associations in THCA, ACC, READ, LUSC, SKCM and UCEC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for VTI1BP4 RNA expression.
This table summarizes VTI1BP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for VTI1BP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VTI1BP4 shows higher tumor expression in COAD and ESCA. The COAD box plot shows higher VTI1BP4 RNA expression in tumor versus normal tissue (log2 FC = +0.042, t-test p = .028).
This table shows molecular features associated with VTI1BP4 in patient tissues and cancer cell lines. In patient samples, VTI1BP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
